Treatment outcomes, health-care resource utilization and costs of bortezomib and dexamethasone, with cyclophosphamide or lenalidomide, in newly diagnosed multiple myeloma
Leukemia 2016 04; 30(4): 995-998. e-pub ahead of print 2015/08/15